0 Table of Contents |
1 Home |
2 Libraries |
3 Measures |
4 Downloads |
5 Artifacts Summary |
5.1 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography in Adults - Facility OQR FHIR |
5.1.1 Library |
5.2 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography in Adults - Clinician FHIR |
5.2.1 Library |
5.3 Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography in Adults - Facility IQR FHIR |
5.3.1 Library |
5.4 Antidepressant Medication ManagementFHIR |
5.4.1 Library |
5.5 Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic FractureFHIR |
5.5.1 Library |
5.6 Appropriate Testing for PharyngitisFHIR |
5.6.1 Library |
5.7 Appropriate Treatment for Upper Respiratory Infection (URI)FHIR |
5.7.1 Library |
5.8 Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation TherapyFHIR |
5.8.1 Library |
5.9 Breast Cancer ScreeningFHIR |
5.9.1 Library |
5.10 Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than or equal to 40%)FHIR |
5.10.1 Library |
5.11 Safe Use of Opioids Concurrent PrescribingFHIR |
5.11.1 Library |
5.12 Anticoagulation Therapy for Atrial Fibrillation/FlutterFHIR |
5.12.1 Library |
5.13 Antithrombotic Therapy By End of Hospital Day 2FHIR |
5.13.1 Library |
5.14 Hospital Harm - Severe HypoglycemiaFHIR |
5.14.1 Library |
5.15 Hospital Harm - Opioid-Related Adverse EventsFHIR |
5.15.1 Library |
5.16 Hospital Harm - Pressure InjuryFHIR |
5.16.1 Library |
5.17 Hospital Harm - Acute Kidney InjuryFHIR |
5.17.1 Library |
5.18 Hospital Harm - Severe HyperglycemiaFHIR |
5.18.1 Library |
5.19 Malnutrition Care ScoreFHIR |
5.19.1 Library |
5.20 Appropriate Treatment for ST-Segment Elevation Myocardial Infarction (STEMI) Patients in the Emergency Department FHIR |
5.20.1 Library |
5.21 Core Clinical Data Elements for the Hybrid Hospital Wide Readmission Measure with Claims and Electronic Health Record Data HWRFHIR |
5.21.1 Library |
5.22 Core Clinical Data Elements for the Hybrid Hospital Wide All Condition All Procedure Risk Standardized Mortality Measure HWMFHIR |
5.22.1 Library |
5.23 Closing the Referral Loop: Receipt of Specialist ReportFHIR |
5.23.1 Library |
5.24 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract SurgeryFHIR |
5.24.1 Library |
5.25 Cervical Cancer ScreeningFHIR |
5.25.1 Library |
5.26 Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk AssessmentFHIR |
5.26.1 Library |
5.27 Childhood Immunization StatusFHIR |
5.27.1 Library |
5.28 Children Who Have Dental Decay or CavitiesFHIR |
5.28.1 Library |
5.29 Chlamydia Screening in WomenFHIR |
5.29.1 Library |
5.30 Colorectal Cancer ScreeningFHIR |
5.30.1 Library |
5.31 Controlling High Blood PressureFHIR |
5.31.1 Library |
5.32 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes CareFHIR |
5.32.1 Library |
5.33 Dementia: Cognitive AssessmentFHIR |
5.33.1 Library |
5.34 Depression Remission at Twelve MonthsFHIR |
5.34.1 Library |
5.35 Diabetes: Eye ExamFHIR |
5.35.1 Library |
5.36 Diabetes: Glycemic Status Assessment Greater Than 9%FHIR |
5.36.1 Library |
5.37 Discharged on Antithrombotic TherapyFHIR |
5.37.1 Library |
5.38 Documentation of Current Medications in the Medical RecordFHIR |
5.38.1 Library |
5.39 Falls: Screening for Future Fall RiskFHIR |
5.39.1 Library |
5.40 Follow-Up Care for Children Prescribed ADHD Medication (ADD)FHIR |
5.40.1 Library |
5.41 Functional Status Assessment for Total Hip ReplacementFHIR |
5.41.1 Library |
5.42 Functional Status Assessments for Heart FailureFHIR |
5.42.1 Library |
5.43 Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)FHIR |
5.43.1 Library |
5.44 Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)FHIR |
5.44.1 Library |
5.45 HIV Annual Retention in CareFHIR |
5.45.1 Library |
5.46 Sexually Transmitted Infection (STI) Testing for People with HIVFHIR |
5.46.1 Library |
5.47 HIV ScreeningFHIR |
5.47.1 Library |
5.48 HIV Viral SuppressionFHIR |
5.48.1 Library |
5.49 Initiation and Engagement of Substance Use Disorder TreatmentFHIR |
5.49.1 Library |
5.50 Intensive Care Unit Venous Thromboembolism ProphylaxisFHIR |
5.50.1 Library |
5.51 Intravesical Bacillus-Calmette-Guerin for Non-Muscle Invasive Bladder CancerFHIR |
5.51.1 Library |
5.52 Kidney Health EvaluationFHIR |
5.52.1 Library |
5.53 Oncology: Medical and Radiation Pain Intensity QuantifiedFHIR |
5.53.1 Library |
5.54 Preventive Care and Screening Body Mass Index Screening and Follow Up PlanFHIR |
5.54.1 Library |
5.55 Preventive Care and Screening Screening for High Blood Pressure and Follow Up DocumentedFHIR |
5.55.1 Library |
5.56 Preventive Care and Screening: Screening for Depression and Follow-Up PlanFHIR |
5.56.1 Library |
5.57 Primary Open-Angle Glaucoma (POAG): Optic Nerve EvaluationFHIR |
5.57.1 Library |
5.58 Preventive Care and Screening: Tobacco Use: Screening and Cessation InterventionFHIR |
5.58.1 Library |
5.59 Primary Caries Prevention Intervention as Offered by DentistsFHIR |
5.59.1 Library |
5.60 Prostate Cancer Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer PatientsFHIR |
5.60.1 Library |
5.61 Severe Obstetric ComplicationsFHIR |
5.61.1 Library |
5.62 Statin Therapy for the Prevention and Treatment of Cardiovascular DiseaseFHIR |
5.62.1 Library |
5.63 Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic HyperplasiaFHIR |
5.63.1 Library |
5.64 Use of High-Risk Medications in Older AdultsFHIR |
5.64.1 Library |
5.65 Venous Thromboembolism ProphylaxisFHIR |
5.65.1 Library |
5.66 Weight Assessment and Counseling for Nutrition and Physical Activity for Children/AdolescentsFHIR |
5.66.1 Library |
5.67 AHAOverall |
5.68 ALARACTOQRFHIR |
5.69 AdultOutpatientEncounters |
5.70 AdvancedIllnessandFrailty |
5.71 AlaraCTClinicalFHIR |
5.72 AlaraCTIQRFHIR |
5.73 AlaraCommonFunctions |
5.74 Antibiotic |
5.75 AntidepressantMedicationManagementFHIR |
5.76 AppropriateDXAScansForWomenUnder65FHIR |
5.77 AppropriateTestingforPharyngitisFHIR |
5.78 |
5.79 AppropriateTreatmentforUpperRespiratoryInfectionURIFHIR |
5.80 BoneDensityProstateCancerAndrogenDeprivationTherapyFHIR |
5.81 BreastCancerScreeningFHIR |
5.82 CADBetaBlockerTherapyPriorMIorLVSDFHIR |
5.83 CMS506FHIRSafeUseofOpioids |
5.84 CMS71FHIRSTKAnticoagAFFlutter |
5.85 CMS72FHIRSTKAntithromboticDay2 |
5.86 CMS816HHHypoFHIR |
5.87 CMS819HHORAEFHIR |
5.88 CMS826HHPIFHIR |
5.89 CMS832HHAKIFHIR |
5.90 CMS871HHHyperFHIR |
5.91 CMS986FHIRMalnutritionScore |
5.92 CMS996FHIRAptTxforSTEMI |
5.93 CMSFHIR529HybridHospitalWideReadmission |
5.94 CMSFHIR844HybridHospitalWideMortality |
5.95 CQMCommon |
5.96 CRLReceiptofSpecialistReportFHIR |
5.97 Cataracts2040BCVAwithin90DaysFHIR |
5.98 CervicalCancerScreeningFHIR |
5.99 ChildandAdolescentMajorDepressiveDisorderMDDSuicideRiskAssessmentFHIR |
5.100 ChildhoodImmunizationStatusFHIR |
5.101 ChildrenWhoHaveDentalDecayOrCavitiesFHIR |
5.102 ChlamydiaScreeninginWomenFHIR |
5.103 ColonCancerScreeningFHIR |
5.104 ControllingHighBloodPressureFHIR |
5.105 CumulativeMedicationDuration |
5.106 DRCommunicationWithPhysicianManagingDiabetesFHIR |
5.107 DementiaCognitiveAssessmentFHIR |
5.108 DepressionRemissionatTwelveMonthsFHIR |
5.109 DiabetesEyeExamFHIR |
5.110 DiabetesGlycemicStatusAssessmentGreaterThan9PercentFHIR |
5.111 DischargedonAntithromboticTherapyFHIR |
5.112 DocumentationofCurrentMedicationsFHIR |
5.113 FHIRHelpers |
5.114 FallsScreeningForFutureFallRiskFHIR |
5.115 |
5.116 FollowUpCareforChildrenPrescribedADHDMedicationADDFHIR |
5.117 FunctionalStatusAssessmentforTotalHipReplacementFHIR |
5.118 FunctionalStatusAssessmentsforHeartFailureFHIR |
5.119 |
5.120 HFACEIorARBorARNIforLVSDFHIR |
5.121 HFBetaBlockerTherapyforLVSDFHIR |
5.122 HIVRetentionFHIR |
5.123 HIVSTITestingFHIR |
5.124 HIVScreeningFHIR |
5.125 HIVViralSuppressionFHIR |
5.126 Hospice |
5.127 |
5.128 |
5.129 |
5.130 |
5.131 |
5.132 |
5.133 |
5.134 InitiationandEngagementofSubstanceUseDisorderTreatmentFHIR |
5.135 IntensiveCareUnitVenousThromboembolismProphylaxisFHIR |
5.136 IntravesicalBacillusCalmetteGuerinForBladderCancerFHIR |
5.137 KidneyHealthEvaluationFHIR |
5.138 OncologyPainIntensityQuantifiedFHIR |
5.139 PCMaternal |
5.140 PCSBMIScreenAndFollowUpFHIR |
5.141 PCSBPScreeningFollowUpFHIR |
5.142 PCSDepressionScreenAndFollowUpFHIR |
5.143 POAGOpticNerveEvaluationFHIR |
5.144 PalliativeCare |
5.145 PreventiveCareAndTobaccoUseScreeningAndCessationInterventionFHIR |
5.146 PrimaryCariesPreventionasOfferedbyDentistsFHIR |
5.147 ProstateCaAvoidanceBoneScanOveruseFHIR |
5.148 QICoreCommon |
5.149 SevereObstetricComplicationsFHIR |
5.150 StatinTherapyforthePreventionandTreatmentofCardiovascularDiseaseFHIR |
5.151 Status |
5.152 SupplementalDataElements |
5.153 TJCOverall |
5.154 UrinarySymptomScoreChangeAfterBenignProstaticHyperplasiaFHIR |
5.155 UseofHighRiskMedicationsintheElderlyFHIR |
5.156 VTE |
5.157 VenousThromboembolismProphylaxisFHIR |
5.158 WeightAssessmentandCounselingforNutritionandPhysicalActivityforChildrenandAdolescentsFHIR |